Default Category
-
U.S. Universities and Technology Transfer
Hamermesh, Richard G.; Lerner, Josh; Andrews, PhillipCase HBS-812016-EEntrepreneurshipTechnology transfer from U.S. universities to industry has increased dramatically in the last 25 years. Reviews the history of technology transfer with particular emphasis on the Bayh-Dole Act of 1980. It then examines how universities responded to Bayh-Dole, the growth of technology transfer offices, and compares how three different universities (MIT, Stanford, and Harvard) approach technology transfer. Provides an overview of the technology tra...Starting at €8.20
-
Gene Patents (A)
Hamermesh, Richard G.; Kiron, David; Andrews, PhillipCase HBS-811089-EEntrepreneurshipIn March 2010, U.S. District Court Judge Robert Sweet overturned 30 years of legal precedent and ruled that unaltered human genes could not be patented. This case reviews patent law and how it relates to our increasing knowledge of the Human Genome. The case issues deal with the potential implications of Judge Sweet's decision for biotechnology entrepreneurs and investors.Starting at €8.20
-
Innovating at AT&T: Partnering to Lead the Broadband Revolution
Applegate, Lynda M.; Andrews, Phillip; Herman, KerryCase HBS-812124-EEntrepreneurshipTo maximize their effectiveness, color cases should be printed in color. In 2010, the U.S. retail market value for next-generation non-handset wirelessly-enabled devices was just over $1 billion. By 2011 it had grown 1,141% to $13.2 billion and was forecast to reach $24.7 billion in 2015. At the same time, user demand for data was surging with the popularity of mobile Internet, e-mail, and messaging, which left carriers scrambling to increase net...Starting at €8.20
-
Poppy (B)
Eisenmann, Thomas R.; Kominers, Scott Duke; Huizinga, Jeff; Ciechanover, Allison M.Case HBS-820715-EEntrepreneurshipAvni Patel Thompson, founder and CEO of Poppy, an online marketplace for on-demand childcare, revisits the venture's final months, and discusses the steps she took in the wake of the shutdown. This case explores experiments the company conducted to refineStarting at €5.74
-
Dinesh Moorjani and Hatch Labs
Ghosh, Shikhar; Stanton, Christopher; Ciechanover, Allison M.; Huizinga, JeffCase HBS-818026-EEntrepreneurshipThis case is about Tinder. It discusses different business models and ways of structuring the initial team. With a $6 million investment from IAC/Interactive in 2010, Dinesh Moorjani founded Hatch Labs to build mobile apps. His mission was to attract entrepreneurial talent to work on Lab projects which, after gaining traction, could be acquired by IAC or spun out as independent companies. To pitch talent to work at Hatch, Moorjani laid out a fram...Starting at €8.20
-
Poppy: A Modern Village for Childcare
Eisenmann, Thomas R.; Huizinga, JeffCase HBS-818075-EEntrepreneurshipIn 2017, management at Poppy, which matched families that required occasional childcare with thoroughly vetted caregivers, was formulating plans for the Seattle-based seed-stage startup's next phase of expansion. One option was to grow using the same business model through geographic expansion to cities beyond Seattle. Another option was to deepen penetration within Seattle by recruiting caregivers with less experience and by broadening the range...Starting at €8.20
-
Gene Patents (B)
Hamermesh, Richard G.; Andrews, PhillipCase HBS-812130-EEntrepreneurshipThe case updates events since the Court's ruling against Myriad Genetics on March 29, 2010 and should be used in conjunction with Gene Patents (A). On July 29, 2011, a US Appeals Court reversed the prior ruling against Myriad. On September 16, 2011, the first major overhaul of US Patent law in nearly 60 years was signed into law. Among other provisions, the law moved the US to a first to-file priority when granting patents, as was the practice...Starting at €5.74
-
Companion Diagnostics: Uncertainties for Approval and Reimbursement
Hamermesh, Richard G.; Selby, Norman C; Andrews, PhillipCase HBS-813037-EEntrepreneurshipThe FDA approvals of novel therapeutics were seen as signs in the personalized medicine community of real progress in the growth of personalized medicine; The FDA's approval of such drugs, along with companion diagnostics, suggested a shift in thinking and regulatory practices at the agency. Beyond the regulatory questions, many considered the reimbursement system archaic, dispersed, unpredictable, and unnecessarily time consuming. Many questione...Starting at €8.20